Teladoc Health, Inc.(TDOC)Earnings, Financials & Key RatiosTeladoc Health, Inc. (TDOC) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company continues to report significant net losses, including a $63.8 million loss in 2026Q1, while struggling to convert revenue into sustainable operating cash flow.
Teladoc Health, Inc. (TDOC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Teladoc Health, Inc. (TDOC) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.36vs $0.34-5.5% | $614Mvs $611M+0.5% |
| Q1 2026 | Feb 25, 2026 | $0.14vs $0.19+26.3% | $642Mvs $635M+1.1% |
| Q4 2025 | Oct 29, 2025 | $0.21vs $0.26+19.2% | $626Mvs $635M-1.4% |
| Q3 2025 | Jul 29, 2025 | $0.19vs $0.27+29.6% | $632Mvs $628M+0.7% |
Recent stock market news and headlines for Teladoc Health, Inc. (TDOC)
Teladoc's business is slowly improving due to several initiatives. However, the company still faces potential headwinds that could derail its progress.
The latest trading day saw Teladoc (TDOC) settling at $8.48, representing a -2.42% change from its previous close.
Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial organizations SURPRISE, Ariz., June 29, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a leader in fertility control solutions for managing rodent populations, today announced the appointment of Jack Karabees as Executive Vice President of Sales.
Teladoc (TDOC) concluded the recent trading session at $7.81, signifying a +1.56% move from its prior day's close.
Key metrics vs top competitors for Teladoc Health, Inc. (TDOC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.10 | $1.64B | -7.98 | -1.54% | -7.92% | -13.93% | — | |
| $9.29 | $155.22M | -1.56 | -1.98% | -48.16% | -33.48% | — | |
| $38.28 | $8.4B | 75.06 | 59% | -0.56% | -2.48% | — | |
| $22.86 | $4.28B | 23.33 | 13.05% | 30.4% | 19.36% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $45.24 | $2.06B | 1021.22 | 6.53% | 1.67% | 1.64% | — |
Teladoc Health, Inc. (TDOC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Teladoc Health, Inc. (TDOC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 29, 2026·SEC
Mar 30, 2026·SEC
Feb 25, 2026·SEC
Get notified when TDOC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Teladoc Health, Inc. (TDOC) stock FAQ — growth, dividends, profitability & financials explained
Teladoc Health, Inc. (TDOC) reported $2.51B in revenue for fiscal year 2025. This represents a 12532% increase from $19.9M in 2013.
Teladoc Health, Inc. (TDOC) saw revenue decline by 1.5% over the past year.
Teladoc Health, Inc. (TDOC) reported a net loss of $171.1M for fiscal year 2025.
Teladoc Health, Inc. (TDOC) has a return on equity (ROE) of -13.9%. Negative ROE indicates the company is unprofitable.
Teladoc Health, Inc. (TDOC) generated $251.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
